Skip to main content
. 2022 Jul 6;10(7):1082. doi: 10.3390/vaccines10071082

Table 2.

Characteristics of COVID-19-positive participants by the immunization schedules.

Total Schedule 0–14 Schedule 0–28
(n = 58) (n = 34) (n = 24)
Age in years, n (%)
18–59 48 (82.8) 29 (85.3) 19 (79.2)
60–98 10 (17.2) 5 (14.7) 5 (20.8)
Sex, n (%)
Female 31 (53.4) 18 (52.9) 13 (54.2)
Clinical score, n (%)
2 (symptomatic, independent) 55 (94.8) 33 (97.1) 22 (91.7)
3 (symptomatic, assistance needed) 1 (1.7) 0 (0.0) 1 (4.1)
5 (hospitalized, oxygen by mask or nasal prongs) 1 (1.7) 1 (2.9) 0 (0.0)
7 (intubation and mechanical ventilation) 1 (1.7) 0 (0.0) 1 (4.1)
Severity criteria, n (%)
Hospitalizations 2 (3.4) 1 (2.9) 1 (4.1)
UCI admissions 1 (1.7) 0 (0.0) 1 (4.1)
Deaths 0 (0.0) 0 (0.0) 0 (0.0)
Health setting workers, n (%)
Yes 28 (48.3) 19 (55.9) 9 (37.5)
Comorbidities, n (%)
≥1 26 (44.8) 14 (41.2) 12 (50.0)
Comorbidities, n (%)
Cardiovascular disease 4 (6.9) 2 (5.9) 2 (8.3)
Asthma and COPD * 6 (10.3) 3 (8.8) 3 (12.5)
Diabetes 3 (5.2) 2 (5.9) 1 (4.2)
Insulin resistance 5 (8.6) 1 (2.9) 4 (16.7)
Arterial hypertension 14 (24.1) 9 (26.5) 5 (20.8)
Allergic rhinitis 7 (12.1) 3 (8.8) 4 (16.7)
Thyroid disease 3 (5.2) 3 (8.8) 0 (0.0)
Obesity 14 (24.1) 5 (14.7) 9 (37.5)
Dyslipidaemia 0 (0.0) 0 (0.0) 0 (0.0)

* COPD: chronic obstructive pulmonary disease. Data are presented as frequency and percentage of the total number of cases in each subgroup and were compared with chi-square test or Fisher exact test; all p values were higher than 0.05.